AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of $335.74 billion. The enterprise value is $401.07 billion.
Important Dates
The last earnings date was Friday, April 25, 2025, before market open.
| Earnings Date | Apr 25, 2025 |
| Ex-Dividend Date | Apr 15, 2025 |
Share Statistics
AbbVie has 1.77 billion shares outstanding. The number of shares has increased by 0.03% in one year.
| Current Share Class | 1.77B |
| Shares Outstanding | 1.77B |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 0.08% |
| Owned by Institutions (%) | 73.60% |
| Float | 1.77B |
Valuation Ratios
The trailing PE ratio is 81.23 and the forward PE ratio is 14.92. AbbVie's PEG ratio is 1.12.
| PE Ratio | 81.23 |
| Forward PE | 14.92 |
| PS Ratio | 5.69 |
| Forward PS | 5.41 |
| PB Ratio | 229.62 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 21.85 |
| P/OCF Ratio | 20.50 |
| PEG Ratio | 1.12 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 14.66, with an EV/FCF ratio of 26.07.
| EV / Earnings | 96.53 |
| EV / Sales | 6.99 |
| EV / EBITDA | 14.66 |
| EV / EBIT | 21.09 |
| EV / FCF | 26.07 |
Financial Position
The company has a current ratio of 0.76, with a Debt / Equity ratio of 47.90.
| Current Ratio | 0.76 |
| Quick Ratio | 0.48 |
| Debt / Equity | 47.90 |
| Debt / EBITDA | 2.53 |
| Debt / FCF | 4.55 |
| Interest Coverage | 6.68 |
Financial Efficiency
Return on equity (ROE) is 88.40% and return on invested capital (ROIC) is 15.45%.
| Return on Equity (ROE) | 88.40% |
| Return on Assets (ROA) | 8.34% |
| Return on Invested Capital (ROIC) | 15.45% |
| Return on Capital Employed (ROCE) | 19.06% |
| Revenue Per Employee | $1.04M |
| Profits Per Employee | $75,545 |
| Employee Count | 55,000 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 3.79 |
Taxes
| Income Tax | -581.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.22% in the last 52 weeks. The beta is 0.55, so AbbVie's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | +18.22% |
| 50-Day Moving Average | 195.94 |
| 200-Day Moving Average | 189.35 |
| Relative Strength Index (RSI) | 51.27 |
| Average Volume (20 Days) | 8,015,635 |
Short Selling Information
The latest short interest is 19.80 million, so 1.12% of the outstanding shares have been sold short.
| Short Interest | 19.80M |
| Short Previous Month | 17.14M |
| Short % of Shares Out | 1.12% |
| Short % of Float | 1.12% |
| Short Ratio (days to cover) | 2.02 |
Income Statement
In the last 12 months, AbbVie had revenue of $57.37 billion and earned $4.16 billion in profits. Earnings per share was $2.34.
| Revenue | 57.37B |
| Gross Profit | 40.74B |
| Operating Income | 19.02B |
| Pretax Income | n/a |
| Net Income | 4.16B |
| EBITDA | 27.37B |
| EBIT | 19.02B |
| Earnings Per Share (EPS) | $2.34 |
Full Income StatementBalance Sheet
The company has $5.18 billion in cash and $70.02 billion in debt, giving a net cash position of -$64.85 billion or -$36.71 per share.
| Cash & Cash Equivalents | 5.18B |
| Total Debt | 70.02B |
| Net Cash | -64.85B |
| Net Cash Per Share | -$36.71 |
| Equity (Book Value) | 1.46B |
| Book Value Per Share | 0.80 |
| Working Capital | -8.73B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $16.40 billion and capital expenditures -$1.02 billion, giving a free cash flow of $15.39 billion.
| Operating Cash Flow | 16.40B |
| Capital Expenditures | -1.02B |
| Free Cash Flow | 15.39B |
| FCF Per Share | $8.71 |
Full Cash Flow StatementMargins
Gross margin is 71.01%, with operating and profit margins of 33.15% and 7.31%.
| Gross Margin | 71.01% |
| Operating Margin | 33.15% |
| Pretax Margin | 6.31% |
| Profit Margin | 7.31% |
| EBITDA Margin | 47.70% |
| EBIT Margin | 33.15% |
| FCF Margin | 26.82% |
Dividends & Yields
This stock pays an annual dividend of $6.56, which amounts to a dividend yield of 3.45%.
| Dividend Per Share | $6.56 |
| Dividend Yield | 3.45% |
| Dividend Growth (YoY) | 5.28% |
| Years of Dividend Growth | 53 |
| Payout Ratio | 280.35% |
| Buyback Yield | -0.03% |
| Shareholder Yield | 3.42% |
| Earnings Yield | 1.24% |
| FCF Yield | 4.58% |
Dividend DetailsAnalyst Forecast
The average price target for AbbVie is $212.00, which is 11.54% higher than the current price. The consensus rating is "Buy".
| Price Target | $212.00 |
| Price Target Difference | 11.54% |
| Analyst Consensus | Buy |
| Analyst Count | 23 |
| Revenue Growth Forecast (5Y) | 6.73% |
| EPS Growth Forecast (5Y) | 50.71% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AbbVie has an Altman Z-Score of 2.14 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.14 |
| Piotroski F-Score | 6 |